Clinical Trial Update: Study of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 Sustained Release (SR) in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating flexible doses of EB-1020 SR for adult ADHD has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• EB-1020 Sustained Release (EB-1020)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Adult ADHD | Phase 2 | Status: COMPLETED | Results posted: 2021-10-18